Xavian 15mg Tablet contains Rivaroxaban, an oral anticoagulant classified as a direct factor Xa inhibitor. It is primarily indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban exerts its anticoagulant effect by selectively inhibiting factor Xa, a key enzyme in the coagulation cascade responsible for the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation. Xavian 15mg is typically administered once or twice daily depending on the clinical indication and patient-specific factors. The medication offers the advantage of fixed dosing without the need for routine coagulation monitoring, unlike traditional vitamin K antagonists. However, it should be used with caution in patients with renal impairment, hepatic dysfunction, or increased bleeding risk. Common adverse effects include bleeding, anemia, and gastrointestinal disturbances. Contraindications include active pathological bleeding and hypersensitivity to Rivaroxaban. Patients should be advised to report any signs of unusual bleeding or bruising promptly. Xavian 15mg Tablet should be prescribed and used under the supervision of a healthcare professional, with appropriate assessment of thrombotic and bleeding risks.